Analyst Price Target is $35.00
▲ +535.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for F-star Therapeutics in the last 3 months. The average price target is $35.00, with a high forecast of $35.00 and a low forecast of $35.00. The average price target represents a 535.21% upside from the last price of $5.51.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in F-star Therapeutics. This Hold consensus rating has held steady for over two years.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.